BRIEF-Pediapharm receives FDA supplement approval regarding Naproxen suspension
May 11 (Reuters) - Pediapharm Inc :
* Approval triggered second and final payment of us$2 million in cash
* Pediapharm receives fda supplement approval regarding naproxen suspension in the us, receives additional us$2 million from atnahs pharma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.